Affiliation:
1. Pirogov Russian National Research Medical University of Ministry of Health of the Russian Federation, Russian Gerontology Research and Clinical Centre
Abstract
Currently the number of older people with chronic rheumatic diseases is increasing. Distinctive features of this population are the increased risk of cardiovascular and infectious diseases, tumours, as well as iatrogenic complications, while this group of patients is rather heterogeneous. On the one hand, modern biological and targeted synthetic drugs, provide new, previously inaccessible, treatment options; on the other hand, their use is associated with risk of side effects. In this review specifics of prescribing immunosuppressive drugs in older patients with rheumatoid arthritis and spondyloarthritis has been analyzed. An effective and safe approach to the use of these drugs in older people can be based on a comprehensive interdisciplinary approach, taking into account geriatric characteristics of the patients.
Publisher
Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology
Reference170 articles.
1. Forouzanfar M.H. et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990– 2015: a systematic analysis for the Global Burden of Disease Study 2015 // Lancet. Lancet Publishing Group, 2016. Vol. 388, № 10053. P. 1659–1724.
2. Franceschi C. et al. Inflamm-aging. An evolutionary perspective on immunosenescence // Annals of the New York Academy of Sciences. New York Academy of Sciences, 2000. Vol. 908. P. 244–254.
3. McElhaney J.E., Effros R.B. Immunosenescence: what does it mean to health outcomes in older adults? // Current Opinion in Immunology. 2009. Vol. 21, № 4. P. 418–424.
4. Bressler R., Bahl J.J. Principles of Drug Therapy for the Elderly Patient // Mayo Clinic Proceedings. Elsevier Ltd, 2003. Vol. 78, № 12. P. 1564–1577.
5. Grimes D.A., Schulz K.F. Bias and causal associations in observational research // Lancet. Elsevier Limited, 2002. Vol. 359, № 9302. P. 248–252.